Combination therapy before surgery for kidney cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new drug combination given before surgery for kidney cancer that is early stage but hard to operate on. The goal is to shrink the tumor and make surgery easier.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Clear cell kidney cancer confirmed by biopsy before surgery.
- Tumor stage T1N0M0 or T2N0M0 with a R.E.N.A.L. score of 10 or higher, meaning the tumor is complex to remove.
- Age between 18 and 80 years old.
- Willing to have kidney-sparing surgery.
- Good overall health with an ECOG score of 0 or 1 (fully active or slightly limited).
- No spread to lymph nodes, no blood vessel involvement, and no metastasis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving pucotenlimab (an immunotherapy drug) with vorolanib (a targeted therapy) before surgery helps shrink clear cell kidney tumors and makes kidney-sparing surgery safer. It is for people with localized, non-metastatic disease where the tumor is difficult to remove with partial nephrectomy.
This trial tests whether giving an immunotherapy drug (PD-L1 inhibitor) and an oral medication (anlotinib) before surgery can help shrink complex kidney tumors so that surgeons can remove only part of the kidney, preserving more kidney function. It may help you avoid losing your whole kidney.
This study tests a new treatment given before surgery for high-risk kidney cancer that hasn't spread far. The goal is to see if it can help shrink the tumor and improve outcomes.
This study tests a new combination of medicines for people with advanced clear cell kidney cancer that has gotten worse after first treatment. The combination includes two immunotherapy drugs (iparomlimab and tuvonralimab) plus one of two targeted therapy pills (lenvatinib or axitinib). The goal is to see if this approach can help control the cancer.
This trial tests a new drug (JS004) combined with an existing immunotherapy (toripalimab) for kidney cancer that has progressed after previous immunotherapy. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests a combination of two immunotherapy drugs (cemiplimab and fianlimab) given before surgery for high-risk kidney cancer that has not spread. The goal is to see if the drugs can help reduce the risk of the cancer coming back or spreading in the future.
Hear when a new Clear Cell Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.